万古霉素治疗药物浓度监测队列研究  

A cohort study of vancomycin therapeutic drug monitoring

作　　者：梁晓宇[1] 吴菊芳[1] 杨敏婕[1] 范亚新[1] 郁继诚[1] 曹国英[1] 黄俊[1] 周颖杰[1] 张菁[1] 

机构地区：[1]复旦大学附属华山医院抗生素研究所,卫生部抗生素临床药理重点实验室,上海200040

出　　处：《中国感染与化疗杂志》2015年第5期472-478,共7页Chinese Journal of Infection and Chemotherapy

摘　　要：目的了解革兰阳性菌感染患者根据治疗药物浓度监测结果调整万古霉素给药方案的有效性和安全性。方法收集复旦大学附属华山医院2005年1月—2014年9月进行万古霉素治疗药物浓度监测(TDM)的住院患者128例,分为治疗方案调整组和未调整组进行TDM数据、万古霉素疗效、安全性分析,并建立Cox模型和生存曲线。结果调整组万古霉素日剂量和血药谷浓度高于未调整组,细菌学疗效和综合疗效也优于未调整组。Cox比例风险模型提示调整给药方案是疗效的保护因素。未发现安全性相关危险因素。结论根据TDM结果调整感染患者万古霉素给药方案,对于提高革兰阳性菌感染患者疗效有重要意义。Objective To evaluate the efficacy and safety of therapeutic drug monitoring （TDM ） based vancomycin dose adjustment in patients with gram‐positive infections .Methods A cohort study was designed with 128 inpatients undergoing TDM in Huashan Hospital from January 2005 to September 2014 .The clinical data of these patients were used to analyze the efficacy and safety of vancomycin therapy by Cox model and survival analysis .Results The patients undergoing TDM‐based dose adjustment had a higher daily dose and blood trough concentration ,which may lead to better bacteriological efficacy and overall efficacy .Cox proportional hazards model analysis showed that TDM‐based dose adjustment is a protective factor .No safety‐related risk factor was found .Conclusions TDM‐based vancomycin dose adjustment is important for patients to achieve better outcomes in fighting gram‐positive infections .

关 键 词：万古霉素 治疗药物浓度监测 队列研究 

分 类 号：R969[医药卫生—药理学]